ClinicalTrials.gov
public full text
Public Domain
Brain Changes in Psoriasis After Secukinumab Treatment
The purpose of this study is to assess the effect of a biologic drug targeting the Interleukin (IL)-17 pathway (secukinumab) on brain plasticity and examine whether the plastic changes correlate with the improvement of perception of well-being, itch, and pain in participants with psoriasis.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery#152584
- Neuromodulation Augmented Cognitive Training to Improve Cognitive Flexibility in Anorexia Nervosa#912930
- A longitudinal atlas of human psoriatic skin reveals the mechanisms of anti-IL-23 therapy in disrupting the type 17 inflammatory circuit.#312569
- Efficacy of tDCS on Pain in Multiple Sclerosis#1151599
- Transcranial Direct Current Stimulation (tDCS) in Different Psychiatric Disorders#892561
Record · ID 1072564
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive